Summit Therapeutics (SMMT) Net Income towards Common Stockholders (2019 - 2024)
Summit Therapeutics (SMMT) posted Net Income towards Common Stockholders of -$72.9 million for Q4 2024, down 19.87% on a QoQ basis from -$60.8 million in Q3 2024, and down 86.26% year-over-year from -$530.7 million in Q1 2024.
Summit Therapeutics (SMMT) Net Income towards Common Stockholders (2019 - 2024) Analysis & Trends
Summit Therapeutics' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$72.9 million for Q4 2024.
- Quarterly Net Income towards Common Stockholders fell 86.26% year-over-year to -$72.9 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$72.9 million (up 64.98% YoY) and the FY2024 annual result came in at -$1.9 billion, down 209.59% from the prior year.
- Net Income towards Common Stockholders was -$72.9 million for Q4 2024 at Summit Therapeutics, down from -$60.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$6.1 million in Q1 2020 and bottomed at -$544.5 million in Q1 2023.
- A 5-year average of -$54.2 million and a median of -$21.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 2324.91% — and 2024, when it surged 91.64%.
- Summit Therapeutics' Net Income towards Common Stockholders stood at -$13.5 million in 2020, then plunged by 100.13% to -$27.1 million in 2021, then increased by 25.09% to -$20.3 million in 2022, then plunged by 92.86% to -$39.1 million in 2023, then slumped by 86.26% to -$72.9 million in 2024.
- Business Quant data shows SMMT's Net Income towards Common Stockholders at -$72.9 million in Q4 2024, -$60.8 million in Q3 2024, and -$62.7 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -72.92 Mn |
| Sep 30, 2024 | -60.83 Mn |
| Jun 30, 2024 | -62.72 Mn |
| Mar 31, 2024 | -45.51 Mn |
| Dec 31, 2023 | -39.15 Mn |
| Sep 30, 2023 | -23.41 Mn |
| Jun 30, 2023 | -19.28 Mn |
| Mar 31, 2023 | -544.51 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -17.63 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -22.46 Mn |
| Dec 31, 2021 | -27.10 Mn |
| Sep 30, 2021 | -19.60 Mn |
| Jun 30, 2021 | -24.42 Mn |
| Mar 31, 2021 | -17.49 Mn |
| Dec 31, 2020 | -13.54 Mn |
| Sep 30, 2020 | -17.74 Mn |
| Jun 30, 2020 | -15.28 Mn |
| Mar 31, 2020 | -6.13 Mn |